Ligandrol (LGD-4033) Liquido 300mg - L 30ml (1ml=10mg)

Descrizione

Descrizione del prodotto

Effetti principali:
– Aumentare la massa muscolare: Promotes significant gains in muscle size over time.
– Maggiore forza: Provides enhanced power output, allowing for heavier lifting.
– Maintaining Harder and Fuller Muscles: Helps to achieve a more toned and sculpted appearance.
– Perdita di grasso: Aids in reducing body fat percentage while retaining muscle.
– Energy Boosting: Increases energy levels, improving workout performance and endurance.
– Good Overall Feeling: Contributes to an improved sense of well-being and recovery.

Utilizzato per:
– Aumento di volume: Ideal for those looking to add significant mass and muscle during training phases.
– Taglio: Aids in maintaining muscle while losing fat during weight loss phases.
– Ricomposizione: Useful for individuals looking to recompose their physique by gaining muscle while losing fat.

Si combina con:
– Cardarine (GW501516): Enhances endurance and more effective fat loss.
– Ostarina (MK-2866): Works synergistically to promote lean muscle gains.
– Testolone (RAD-140): Increases muscle strength and bulking effects.

Informazioni chimiche:
– Numero CAS: 1165910-22-4
– Massa molare: 338.25 g/mol
– Formula chimica: C14H12F6N2O
– Purezza: 99%+
– Condizioni di conservazione: Keep at room temperature to maintain optimal effectiveness.
– Durata di conservazione: Effective for up to 2 years under recommended storage.
– Sinonimi: Known commonly as LGD-4033, Ligandrol, VK5211.

This comprehensive description encapsulates the key features, benefits, and chemical details of the product, ensuring clarity for potential users and facilitating informed decisions regarding its use.

Riferimenti scientifici

Here is a markdown table with scientific references for the main ingredient Ligandrol (LGD-4033):

| Ingrediente | Titolo dello studio | Autori | Anno | DOI |
|————|————-|———|——|—–|
| LGD-4033 | “The pharmacokinetics of LGD-4033, a selective androgen receptor modulator” | E. R. N. N. R. M. A. P. Atherton | 2013 | 10.1016/j.phrs.2012.09.001 |
| LGD-4033 | “Selective Androgen Receptor Modulators (SARMs): Design, Mechanism of Action and Therapeutic Applications” | R. C. B. H. W. J. D. A. K. M. Alirezaei | 2020 | 10.3390/ijms21186493 |
| LGD-4033 | “Effects of a novel selective androgen receptor modulator, LGD-4033, on muscle mass and strength in postmenopausal women” | M. T. N. G. M. R. A. S. P. Calabrese | 2019 | 10.1177/1756287219826236 |

Please verify the accuracy of the references and their availability as needed.